Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring

被引:25
作者
Netterberg, Ida [1 ]
Nielsen, Elisabet I. [1 ]
Friberg, Lena E. [1 ]
Karlsson, Mats O. [1 ]
机构
[1] Uppsala Univ, Dept Pharmaceut Biosci, Box 591, S-75124 Uppsala, Sweden
关键词
Self-monitoring of ANC; Model-based predictions; Chemotherapy-induced myelosuppression; Docetaxel; COLONY-STIMULATING FACTOR; BREAST-CANCER PATIENTS; CHEMOTHERAPY-INDUCED NEUTROPENIA; CLINICAL-PRACTICE GUIDELINE; FEBRILE NEUTROPENIA; ADJUVANT CHEMOTHERAPY; AMERICAN SOCIETY; 2010; UPDATE; G-CSF; ONCOLOGY;
D O I
10.1007/s00280-017-3366-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose To investigate whether a more frequent monitoring of the absolute neutrophil counts (ANC) during myelo-suppressive chemotherapy, together with model-based predictions, can improve therapy management, compared to the limited clinical monitoring typically applied today. Methods Daily ANC in chemotherapy-treated cancer patients were simulated from a previously published population model describing docetaxel-induced myelosuppression. The simulated values were used to generate predictions of the individual ANC time-courses, given the myelosuppression model. The accuracy of the predicted ANC was evaluated under a range of conditions with reduced amount of ANC measurements. Results The predictions were most accurate when more data were available for generating the predictions and when making short forecasts. The inaccuracy of ANC predictions was highest around nadir, although a high sensitivity (>= 90%) was demonstrated to forecast Grade 4 neutropenia before it occurred. The time for a patient to recover to baseline could be well forecasted 6 days (+/- 1 day) before the typical value occurred on day 17. Conclusions Daily monitoring of the ANC, together with model-based predictions, could improve anticancer drug treatment by identifying patients at risk for severe neutropenia and predicting when the next cycle could be initiated.
引用
收藏
页码:343 / 353
页数:11
相关论文
共 39 条
[1]
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours [J].
Aapro, M. S. ;
Bohlius, J. ;
Cameron, D. A. ;
Dal Lago, Lissandra ;
Donnelly, J. Peter ;
Kearney, N. ;
Lyman, G. H. ;
Pettengell, R. ;
Tjan-Heijnen, V. C. ;
Walewski, J. ;
Weber, Damien C. ;
Zielinski, C. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (01) :8-32
[2]
Alken Scheryll, 2013, Cancer Manag Res, V5, P357, DOI 10.2147/CMAR.S49321
[3]
[Anonymous], MIN HOM PHIL HEALTHC
[4]
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [J].
Azzoli, Christopher G. ;
Baker, Sherman, Jr. ;
Temin, Sarah ;
Pao, William ;
Aliff, Timothy ;
Brahmer, Julie ;
Johnson, David H. ;
Laskin, Janessa L. ;
Masters, Gregory ;
Milton, Daniel ;
Nordquist, Luke ;
Pfister, David G. ;
Piantadosi, Steven ;
Schiller, Joan H. ;
Smith, Reily ;
Smith, Thomas J. ;
Strawn, John R. ;
Trent, David ;
Giaccone, Giuseppe .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6251-6266
[5]
Beal S., 1988, NONMEM User Guides
[6]
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response [J].
Bender, Brendan C. ;
Schindler, Emilie ;
Friberg, Lena E. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (01) :56-71
[7]
Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer [J].
Cameron, DA ;
Massie, C ;
Kerr, G ;
Leonard, RCF .
BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1837-1842
[8]
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients [J].
Chirivella, Isabel ;
Bermejo, Begona ;
Insa, Amelia ;
Perez-Fidalgo, Alejandro ;
Magro, Ana ;
Rosello, Susana ;
Garcia-Garre, Elisa ;
Martin, Paloma ;
Bosch, Ana ;
Lluch, Ana .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) :479-484
[9]
Management of febrile neutropenia: ESMO Clinical Practice Guidelines [J].
de Naurois, J. ;
Novitzky-Basso, I. ;
Gill, M. J. ;
Marti, F. Marti ;
Cullen, M. H. ;
Roila, F. .
ANNALS OF ONCOLOGY, 2010, 21 :v252-v256
[10]
Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis [J].
Debled, M. ;
Houede, N. ;
Madranges, N. ;
Donamaria, C. ;
Floquet, A. ;
Durand, M. ;
Mauriac, Louis .
BRITISH JOURNAL OF CANCER, 2007, 97 (12) :1642-1647